secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001140361-26-015801
Event type: other_material
Sentiment:  positive
Materiality: 0.78
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis zilganersen meets primary endpoint in Alexander disease; PDUFA Sept 22, 2026
--------------------------------------------------------------------------------

- Primary endpoint met: gait speed stabilized vs control at Week 61 (LS mean diff 33.3%, p=0.041) in patients ≥5 years.
- GMFM-88 in children 2-4 years showed 22.9-point improvement vs control (nominal p=0.034).
- Key secondary endpoints (MBS, PGIS, PGIC, CGIC) consistently favored zilganersen over control.
- Serious TEAEs less frequent on zilganersen (37.5%) vs control (47.1%); most AEs mild/moderate.
- FDA Priority Review with PDUFA action date set for September 22, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036126015801/0001140361-26-015801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036126015801/ef20071051_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-015801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer